American Association for Cancer Research
Browse
00085472can092838-sup-sfig_1.pdf (2.59 MB)

Supplementary Figure 1 from A Novel Mouse Model for De novo Melanoma

Download (2.59 MB)
journal contribution
posted on 2023-03-30, 19:25 authored by Mayuko Y. Kumasaka, Ichiro Yajima, Khaled Hossain, Machiko Iida, Toyonori Tsuzuki, Tamio Ohno, Masahide Takahashi, Masashi Yanagisawa, Masashi Kato
Supplementary Figure 1 from A Novel Mouse Model for De novo Melanoma

History

ARTICLE ABSTRACT

Nevus-associated melanomas arise from pre-existing benign lesions, but de novo melanomas can also develop in the absence of such lesions. Few studies have addressed the latter phenomenon because no animal models have been described in which melanomas clearly develop in a de novo manner. In this study, we have address this need in defining RFP-RET-transgenic mice (RET mice) as a mouse model for multi-step melanomagenesis that proceeds via tumor-free, benign, premalignant, and malignant stages. Melanomas from RET mice exhibited decreased expression levels of endothelin receptor B (Ednrb) compared with benign tumors. In RET mice that were heterozygous for Ednrb (Ednrb+/−;RET mice), >80% of the arising primary tumors were malignant. Life span after tumor development in the mice was significantly shorter than in RET mice. Lung metastasis after tumor development was significantly higher than in RET mice. The observed process of melanomagenesis in Ednrb+/−;RET mice, which proceeded without a pre-existing benign lesion, along with the emergent characteristics in the model after tumor development corresponded well with the formation of de novo melanoma in humans. Our findings define a novel transgenic mouse model for de novo melanoma and suggest that reduced expression of Ednrb might facilitate the development of de novo melanoma in humans. Cancer Res; 70(1); 24–9

Usage metrics

    Cancer Research

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC